Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

被引：4
|
作者：
Duerr, Donat [1 ]
Siciliano, Raffaele Daniele [1 ]
Hummel, Yvonne [1 ]
O'Meara, Alix [1 ]
Hirschi, Anita [1 ]
Burkhard, Roger [1 ]
Honegger, Hanspeter [1 ]
机构：
[1] Stadtspital Triemli, CH-8063 Zurich, Switzerland
来源：
ANNALS OF HEMATOLOGY | 2010年 / 89卷 / 01期
关键词：
DELETION; MANAGEMENT; DEL(5Q);
D O I：
10.1007/s00277-009-0775-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [1] Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?
    Donat Dürr
    Raffaele Daniele Siciliano
    Yvonne Hummel
    Alix O’Meara
    Anita Hirschi
    Roger Burkhard
    Hanspeter Honegger
    Annals of Hematology, 2010, 89 : 105 - 106
  • [2] MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE
    Gritsaev, S. V.
    Martinkevitch, I. S.
    Petrova, E. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (02): : 3 - 10
  • [3] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    List, Alan
    Dewald, Gordon
    Bennett, John
    Giagounidis, Aristotle
    Raza, Azra
    Feldman, Eric
    Powell, Bayard
    Greenberg, Peter
    Thomas, Deborah
    Stone, Richard
    Reeder, Craig
    Wride, Kenton
    Patin, John
    Schmidt, Michele
    Zeldis, Jerome
    Knight, Robert
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1456 - 1465
  • [4] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella, Federico
    Latagliata, Roberto
    Carmosino, Ida
    Volpicelli, Paola
    Montagna, Chiara
    Romano, Angela
    Roberto, Amanda
    Finsinger, Paola
    Mancini, Marco
    Breccia, Massimo
    Oliva, Esther
    Alimena, Giuliana
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
  • [5] Lenalidomide in myelodysplastic syndromes with del5q: How long is enough?
    Vozella, F.
    Latagliata, R.
    Carmosino, I.
    Volpicelli, P.
    Montagna, C.
    Romano, A.
    Finsinger, P.
    Breccia, M.
    Oliva, E. N.
    Alimena, G.
    LEUKEMIA RESEARCH, 2013, 37 : S163 - S164
  • [6] Mechanisms of Resistance to Lenalidomide in Del(5q) Myelodysplastic Syndrome Patients
    Martinez-Hoyer, Sergio
    Docking, Rod
    Chan, Simon
    Jadersten, Martin
    Parker, Jeremy
    Karsan, Aly
    BLOOD, 2015, 126 (23)
  • [7] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [8] Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
    Duong, Vu H.
    Komrokji, Rami S.
    List, Alan F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (02) : 105 - 116
  • [9] Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
    Eclache, Virginie
    Da Rocha, Anna
    Le Roux, Genevieve
    Fenaux, Pierre
    HAEMATOLOGICA, 2008, 93 (02) : 315 - 316
  • [10] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
    Talati, Chetasi
    Sallman, David
    List, Alan
    SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
12345